5 results
8-K
EX-99.1
AVIR
Atea Pharmaceuticals Inc
8 May 23
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
4:15pm
quarter ended March 31, 2023 and provided a business update.
“Highlights of the first quarter of 2023 include advancement of our clinical trials and R … &D efforts, together with multiple data presentations at several scientific meetings in support of bemnifosbuvir’s favorable safety and drug
S-1/A
EX-10.8
AVIR
Atea Pharmaceuticals Inc
22 Oct 20
IPO registration (amended)
9:43pm
and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech
DRSLTR
AVIR
Atea Pharmaceuticals Inc
7 Aug 20
Correspondence regarding draft registration statement
12:00am
With reference to your product pipeline table on page 1 and your R&D expense table on page 97, please revise paragraph three to provide an estimate
UPLOAD
AVIR
Atea Pharmaceuticals Inc
16 Jul 20
Letter from SEC
12:00am
on page 1 and your R&D
expense table on
page 97, please revise paragraph three to provide an estimate
regarding how far
- Prev
- 1
- Next